We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Medical House | MLH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 27.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 27.25 | 27.25 |
| Top Posts |
|---|
Posted at 16/9/2009 10:30 by kish_008 I would expect higher than 33p. An interesting article below relating to investors looking for patents. Bodes well for MLH |
Posted at 15/10/2008 08:15 by philjeans Edging up as investors seek out bargains in the ruins.This business model will lead to increasing revenue from licences whilst overheads are kept to the minimum. |
Posted at 31/8/2008 19:20 by red ninja Featured in the Sunday Times ... fairly positive article which suggested that the 30p spike price was not unjustified .... there may be a movement on Monday, but then again the credit chrunch may keep investors money in their pockets. |
Posted at 26/4/2008 18:11 by tonybrookes PhilYes saw this was tipped in the Chronic Investor. Hope this augers well for next week. Tony |
Posted at 06/3/2007 07:16 by ariane Medical House Interim ResultsRNS Number:3555S Medical House PLC 06 March 2007 For Immediate Release 6 March 2007 The Medical House PLC Interim Results for the six months ended 31 December 2006 The Medical House PLC ("TMH") (AIM:MLH) the drug delivery and orthopaedic devices company, announces its interim results for the six months ended 31 December 2006. * Financial Performance * Operating loss reduced by 25% to #473,000 for period when compared to six months ended 30th June 2006 * Turnover #2.7m (2005: #2.9m) * Pre-tax loss before exceptional items #539,000 ( 2005: #392,000) * Drug Delivery Systems * 148% sales increase to #730,000 (2005: #294,000) * #27m deal with major global pharmaceutical company, for customised version of our ASI disposable autoinjector * Discussions ongoing for further licence and development agreements * Orthopaedic Instruments * Turnover of #2.0m (2005: #2.7m) - in line with expectations * Continued effect of major customer experiencing FDA delay - adversely effecting order levels * Restructuring continues to make Orthopaedic business more diverse Executive Chairman, Ian Townsend, said: "We are extremely pleased by the performance of our drug delivery business, which continues to make excellent progress as illustrated by the licence and supply agreement we signed in December 2006 for our ASI disposable autoinjector technology, with a major pharmaceutical company. Our ASI autoinjector technology continues to be favourably received and we remain confident that further development, licence and supply contracts will be signed in due course." For further information: The Medical House PLC tel: 0114 261 9011 Ian Townsend, Executive Chairman www.themedicalhouse. Buchanan Communications tel: 020 7466 5000 Tim Anderson / Rebecca Skye Dietrich Chairman's Statement The Medical House specialises in the development and manufacture of innovative medical devices. The principal operating businesses are: 1. Drug delivery systems: Medical House Products Limited 2. Instruments and implants for the orthopaedic market: Eurocut Limited We are pleased to report that our drug delivery business continues to make excellent progress as illustrated by the significant development, licence and supply agreement we signed in December 2006 for our ASI disposable autoinjector technology. As anticipated when announcing our 2006 annual results on 10 October 2006, Eurocut has continued to find trading in its core orthopaedics market difficult. Therefore, new markets have been targeted with some success but, as expected, volumes from the new activities are low as it takes time to win the confidence of a new customer base. The drug delivery business is a major success in an area which has seen very high valuations placed on companies with profiles similar to The Medical House's. Our orthopaedics activities are based on specialist engineering expertise, but the business is currently diversifying as a result of the soft demand for orthopaedic instruments. The Directors believe that the contrasting performances of the two divisions is causing confusion amongst investors which is suppressing the value of the Group. The directors are therefore actively pursuing a strategy to maximise shareholder value with respect to the orthopaedic business. In our results to 30th June 2006, we announced that we had received approaches for the purchase of our needle-free insulin injector business. We continue to actively explore the possibility of disposing of this element of our activities which no longer fits our business model of licensing and supplying devices solely to pharmaceutical and healthcare company clients. Group Financials The Group is reporting a pre-tax loss before reorganisation costs of #539,000 (2005: #392,000) on sales which were slightly lower at #2.7m (2005: #2.9m) for the six months ended 31st December 2006. This represents a reduced loss to that reported for the six months ended 30th June 2006. Drug Delivery Division: Medical House Products Limited (MHP) Sales in the six months grew by 148% to #730,000 (2005: #294,000) despite the division not yet enjoying major benefits of the anticipated product launches for pharmaceutical company partners' drugs with our needle-free and autoinjector devices. The highlight of the period was undoubtedly the signing of the development, licence and supply agreement with projected sales of #27m, with a major global pharmaceutical company, for a customised version of our ASI disposable autoinjector. This agreement not only has significant financial benefits for the company but also enhances our company's credibility in our marketplace. The development phase of this project is progressing well. Our ASI autoinjector technology continues to be favourably received and we remain confident that further development, licence and supply contracts will be signed in due course. Our ASI device can be used in conjunction with almost any pre-filled syringe and offers major economic, safety and convenience advantages by enabling patients to self-inject their medications without any clinical expertise. This in turn creates significant competitive advantages for pharmaceutical companies who incorporate their injectable drug products within such a device. In the past year a number of self-injected drugs have been successfully launched with pre-filled, disposable autoinjectors and all indications are for this trend to gain further momentum as newly-developed biologic drugs (which are more likely to require injection) are brought to market. Our technology is also extremely adaptable as it can be easily adjusted to vary volume, speed and depth of an injection. This flexibility of the ASI technology allows us to provide clients with a specific solution to their requirements and, as a result, most future agreements for the ASI are likely to involve some form of customisation. In addition to the contracts we have already announced, we have further developed the ASI platform technology with designs well advanced for a "mini" version of the device (for therapies which require users to carry their drugs with them at all times) and a version which automatically mixes dry formulations with liquid diluents, prior to automated injection. In addition to our existing system for delivery of viscous (e.g. sustained release) drugs, these variants within the ASI range of autoinjectors have significant commercial potential and our intellectual property management strategy is focused on protection of this innovation. Sales growth in the short term largely depends on the demand for our clients' drug products which are being partnered with our devices. These products are at various stages of commercialisation but the timing of their commercial launches is in the hands of our customers. However, with the development, licence and supply agreements already in place, we remain very confident of a future of sustained growth for many years to come. Orthopaedic Division: Eurocut Limited Sales in the six months to 31st December were #2m (2005: #2.7m) in line with the expectations we communicated to shareholders in the 2006 year-end results. Sales were held back due to a much quieter overall orthopaedic market which has similarly affected our competitors in the orthopaedic instrumentation field. We were also affected by the continued absence of the orders which have been deferred due to a major customer experiencing delays in US FDA regulatory approval. This particular position has not changed since our last announcement; however, we continue to work closely with our customer on this product line. During the last six months we incurred reorganisation costs of #56,000 due to redundancy expenses, as we continue to restructure Eurocut into a diverse business, serving a variety of markets and with several income streams. With the appointment of additional business development staff and, whilst utilising our existing skills and machinery, our non-orthopaedic orders are steadily increasing and we fully expect this growth to gather momentum in the coming months. New customers invariably wish to see evidence of our capability to produce a quality product in a timely manner. Consequently, small orders are typically received in the first instance, followed by more regular, larger orders. During the past six months we have completed a number of such initial orders for a diverse range of products. Over the next six months we now expect to receive the benefits of these efforts and the volume of our non-orthopaedic business should steadily increase from here. The added advantage of the new areas we have entered is that the margins we are able to achieve are generally much higher than those currently available in orthopaedics. With no signs yet of a major pick up in the orthopaedic market, the recovery in Eurocut's sales and profits will come from these new markets, customers and products. In order to demonstrate our commitment to our new customers in different industries, we have formed a new company, TMH Precision Engineering, which will be responsible for all non-medical work. A new website is being created and a sales force, with experience in relevant markets has been recruited. Eurocut, which has an established brand name in the medical world, will supply only medical products. Outlook The drug delivery division will continue to progress on all fronts and we remain very confident of its continued success in formalising further collaboration agreements and partnerships. Short term results will be influenced by the pace of the recovery at Eurocut, and the performance of the newly-formed TMH Precision Engineering. Meanwhile, given the performance of our orthopaedic operations, and the current depressed market valuation of the Group, the Directors continue to review all strategic options for the orthopaedic and needle-free businesses. Finally, I would like to thank all my colleagues who have worked extremely hard to create a company of which they can all be very proud. Ian Townsend Executive Chairman 6 March 2007 |
Posted at 21/4/2004 12:45 by ariane 6:35am (UK)Elan Licenses Its Nanocrystal Technology to Roche "PA" Business Editors/Health/Medic ATHLONE, Ireland – (BUSINESS WIRE) – April 21, 2004 – Proprietary Elan technology helps improve drug delivery by transforming drugs into more effective and “user friendly” dosage forms to increase patient convenience and compliance. Elan Pharma International Ltd., a subsidiary of Elan Corporation plc, today announced an agreement to license its proprietary NanoCrystal(TM) technology to Roche. NanoCrystal technology can improve the bioavailability of drugs by transforming them into nanometer-sized particles that can be used to create more effective and convenient dosage forms such as tablets, capsules, liquids, and powders. The license agreement will provide Roche with access to NanoCrystal technology and the rights to apply the technology to a drug candidate currently in clinical development. “We are pleased that we are going to continue to work with Roche to apply our NanoCrystal technology to the formulation of this drug candidate,“ said Paul Breen, executive vice president, Global Services & Operations, Elan. “For more than 30 years, Elan has been working to meet the challenges of drug delivery and enhance the performance of drugs. By addressing poor water solubility through the use of NanoCrystal technology, Elan Pharma International Ltd. continues to play a role in furthering the development of drug candidates. In addition, our technology can help companies to differentiate their current therapies from the competition by creating more effective and convenient treatment options for patients.” In the agreement, Elan will provide Roche with formulation services and technology in exchange for research revenues, development milestones and royalties on sales of the product incorporating or made using NanoCrystal technology. “We are pleased to bring our 2003 evaluation agreement with Elan to this next level and are enthusiastic about the potential of NanoCrystal technology,“ said Urs Saner, Roche’s Head of Pharma Technical Development. “This agreement further strengthens our ability to deliver value for patients as we continue to develop innovative, differentiated medicines.” About Elan’s NanoCrystal Technology NanoCrystal technology may enhance the clinical performance of poorly water-soluble drugs by transforming them into nanometer-sized particles. An increasing number of the drug candidates synthesized each year by pharmaceutical companies are poorly water-soluble. Many of these potentially innovative drug candidates are often abandoned because of poor pharmacokinetic properties including absorption, distribution, metabolism, and excretion. NanoCrystal technology has the potential to rescue a significant percentage of these chemical compounds. The drug in nano-form can be incorporated into common dosage forms, including tablets, capsules, inhalation devices, sterile forms for injection, with the potential for substantial improvements to clinical performance. There are currently two pharmaceutical products that have been commercialised incorporating NanoCrystal technology, with several additional product launches anticipated over the next two years. The NanoCrystal technology is protected by 85 issued U.S. patents and 48 pending patents. More information about Elan’s NanoCrystal technology is available at www.nanocrystal.com. About Elan Elan Pharma International Ltd. is an indirect wholly-owned subsidiary of Elan Corporation, plc, which is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock Exchanges. – 30 – DB/ny* CONTACT: Elan Corporation Investors: Emer Reynolds, +353-1-709-4000 800-252-3526 or Media: Anita Kawatra, 212-407-5755 800-252-3526 |
Posted at 23/3/2004 11:29 by grupo guitarlumber RNS Number:8290WMedical House PLC 23 March 2004 For Immediate Release 23 March 2004 The Medical House PLC Appointment of Advisers The Board of The Medical House PLC (the "Company") is pleased to announce the appointments of Code Securities Limited as the Company's financial adviser and Altium Capital Limited as the Company's nominated adviser. The appointments become effective immediately. Canaccord Capital (Europe) Ltd will be retained as the Company's nominated broker. Contacts: The Medical House PLC Ian Townsend, Chief Executive Tel: 0114 261 9011 Code Securities Limited ("Code") is a newly formed London-based investment banking firm providing a full range of advisory, fundraising and stockbroking services for companies and investors in the European life sciences and medtech sectors. Code is an Appointed Representative of Altium Capital Limited. Altium Capital Limited is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange. This information is provided by RNS The company news service from the London Stock Exchange END |
Posted at 11/2/2004 06:21 by byoncee When global growth picks up later this year, investors could profit a great deal from overseas companies. To invest wisely in this economy; you need info on stocks from all over the world. Even small events in the world can affect or alter our investments. That is why, with the help of this true gem, you will get firsthand information on undervalued stocks which are about to move. They have a great track record and will email you only when there is something worth mentioning. You will not receive any junk mail and it will not cost you anything. These shares are traded exclusively in the US markets. |
Posted at 11/2/2004 00:46 by shiny000 I don't hold but came across this snippet today:Independent -11 February 2004 'Brokers tipped Medical House, steady at 42.5p, to start to motor in the coming days as word spreads that Medisys has finally sold its 3.5 per cent stake in the group at 41p. The shares were placed with institutional investors. Dealers reported strong demand among institutions to participate in the placing' |
Posted at 12/11/2003 07:35 by dell314 Waldron - Do you believe that other MLH investors won't be able to find the results without you posting the whole effin' lot?Why not provide a link and just quote the bits that you find interesting, then sensible investors won't have to scroll through reams of stuff that they've already read. Rgds dell |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
